Skip to search formSkip to main contentSkip to account menu

Memantine

Known as: 1-Amino-3,5-dimethyladamantane, 3,5-Dimethyl-1-adamantanamine, 3,5-Dimethyl-1-aminoadamantane 
AMANTADINE derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent.
National Institutes of Health

Related topics

Related topics

22 relations

Broader (4)

AmantadineAntiparkinson AgentsDopaminergic AgentsExcitatory Amino Acid Antagonists

Narrower (8)

AxuraD-145EbixaMemantine hydrochloride
In BloodMemantine hydrochloride 5 MG Oral TabletMemantine:MCnc:Pt:Urine:QnNMDA Receptor Antagonists [MoA]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Cognition as a target in major depression: New developments
Highly Cited
2010
Highly Cited
2010
Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome.
Ts65Dn (TS) mice exhibit several phenotypic characteristics of human Down syndrome, including an increased brain expression of… 
2010
2010
S 24795 Limits β-Amyloid–α7 Nicotinic Receptor Interaction and Reduces Alzheimer's Disease-Like Pathologies
Highly Cited
2006
Highly Cited
2006
Differential pharmacological modulation of the spontaneous stimulus-independent activity in the rat spinal cord following peripheral nerve injury
Highly Cited
2005
Highly Cited
2005
Fluorimetric liquid chromatographic analysis of amantadine in urine and pharmaceutical formulation.
Highly Cited
2004
Highly Cited
2004
Specific Functional Effects of Memantine Treatment in Patients with Moderate to Severe Alzheimer’s Disease
Treatment of Alzheimer’s disease (AD) that combats progressive functional deterioration can improve the patient’s quality of life… 
Highly Cited
2004
Highly Cited
2004
Effects of NMDA receptor antagonists on olfactory learning and memory in the honeybee (Apis mellifera)
Highly Cited
2004
Highly Cited
2004
Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine
Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine 
Highly Cited
2003
Highly Cited
2003
Comparative Study of Action Mechanisms of Dimebon and Memantine on AMPA- and NMDA-Subtypes Glutamate Receptors in Rat Cerebral Neurons
Dimebon in low concentrations potentiated activity of AMPA-receptors in rat cerebellar Purkinje neurons, while memantine produced… 
Highly Cited
1994
Highly Cited
1994
The effect of experimental ischaemia and excitatory amino acid agonists on the GABA and serotonin immunoreactivities in the rabbit retina
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)